Indeed, many RTKs, including cMet and AXL, are overexpressed in malignancy, displaying oncogenic promotion of cancer progression and metastatic disease, so that high cMet expression in melanoma samples has been correlated with a poor clinical outcome [59]. This evidence concerns the gene AXL and cancer.